Cetuximab and paclitaxel combination therapy for recurrent basaloid squamous cell carcinoma in the ethmoid sinus
| Autor: | Satoshi Koyama, Taihei Fujii, Hiromi Takeuchi, Tsuyoshi Morisaki, Takahiro Fukuhara, Kazunori Fujiwara, Yosuke Nakamura |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Paclitaxel medicine.medical_treatment Cetuximab Basaloid squamous cell carcinoma Metastasis Head and neck 03 medical and health sciences 0302 clinical medicine Ethmoid Sinus Antineoplastic Combined Chemotherapy Protocols Chemotherapy Humans Medicine Basal cell carcinoma 030223 otorhinolaryngology Basaloid Squamous Cell Carcinoma Lymph node business.industry General Medicine medicine.disease Magnetic Resonance Imaging Head and neck squamous-cell carcinoma medicine.anatomical_structure Otorhinolaryngology Positron-Emission Tomography 030220 oncology & carcinogenesis Carcinoma Squamous Cell Cancer research Surgery Neoplasm Recurrence Local business Paranasal Sinus Neoplasms Chemoradiotherapy medicine.drug |
| Zdroj: | Koyama, Satoshi. Fujiwara, Kazunori. Morisaki, Tsuyoshi. et al. Cetuximab and paclitaxel combination therapy for recurrent basaloid squamous cell carcinoma in the ethmoid sinus. Auris Nasus Larynx. 48(6), 1189-1192. 2020-07-16. |
| ISSN: | 0385-8146 |
| DOI: | 10.1016/j.anl.2020.07.002 |
| Popis: | Basaloid squamous cell carcinoma (BSCC), a histologically distinctive variant of squamous cell carcinoma comprising basal cell carcinoma and squamous cell carcinoma, is aggressive and shows a poor prognosis because of frequent lymph node invasion and distant metastases. To date few articles regarding chemotherapy for metastatic disease have been reported, thus feasible chemotherapy is not well established. Cetuximab is a monoclonal antibody for epithelial growth factor receptor (EGFR), which has great efficacy for head and neck squamous cell carcinoma due to EGFR signaling pathway blockage. Because BSCC also highly expresses EGFR, cetuximab may be effective for BSCC. We report here a first case of recurrent BSCC in the ethmoid sinus with intracranial extension treated with cetuximab-based chemotherapy, which revealed great response in a 40-year-old man. Positron emission tomography (PET) revealed no lymph node or distant metastasis. The patient underwent chemoradiotherapy 66 Gy in 33 fractions with triweekly 100 mg/m2 cisplatin. However, 12 weeks after treatment completion PET revealed a residual tumor at the primary cancer site. Combination therapy with weekly paclitaxel and cetuximab was started, and complete response was observed 2 months from treatment initiation. The patient has maintained complete response for 32 months, and no tumor regrowth has been observed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect